Related Experiment Video
Updated: Aug 6, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Screening study of serum thrombosis-related target proteins using a specific dabigatran-functionalized material
Shiqi Dong1, Xiaoyan Wang2, Hui Niu1
1State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Dalian 116024, China. hniu@dlut.edu.cn.
Analytical Methods : Advancing Methods and Applications
|July 21, 2026
Summary
A novel magnetic adsorbent using dabigatran was developed to identify drug-related proteins in patient serum. This method successfully screened differential proteins associated with hyperlipidemia/thrombosis/cardiovascular diseases.
Area of Science:
- Biochemistry
- Nanotechnology
- Proteomics
Background:
- Drug-protein interactions are crucial for understanding drug mechanisms and developing new therapeutics.
- Identifying proteins associated with specific diseases and drug treatments is essential for personalized medicine.
Purpose of the Study:
- To develop a novel drug-related protein profiling strategy using a magnetic adsorbent.
- To screen and identify drug-associated proteins in patient serum, particularly for thromboembolic diseases.
Main Methods:
- Fabrication of a magnetic adsorbent (Fe3O4@SiO2@DBG) by immobilizing dabigatran onto Fe3O4@SiO2-NH2 nanomaterial.
- Utilized protein-drug interactions for screening drug-associated proteins in human serum.
- Applied the method to serum samples from patients with hyperlipidemia/thrombosis/cardiovascular disease (HTC) and healthy controls (HC).
Main Results:
- Optimized the screening procedure using healthy human serum as a model.
- Identified a total of 26 differential proteins between HTC patients and healthy controls.
- Functional annotation (GO) and pathway analysis (KEGG) revealed associations with metabolic and signaling pathways relevant to HTC diseases.
Conclusions:
- The developed interaction-oriented protein screening approach provides an innovative platform for drug discovery.
- The identified differential proteins and pathways offer guidance for screening drug targets or biomarkers for thromboembolic diseases.
- This strategy facilitates subsequent mechanism research and drug development for related conditions.
